Weight loss drugs have gained popularity in recent times, with several options available for those seeking to shed pounds. Mounjaro and Wegovy are two of the most notable ones approved for weight loss, while Ozempic is a well-known medication for Type-2 diabetes that also has a significant impact on weight.
These medications work similarly by reducing hunger and appetite, leading to less food consumption. However, like all drugs, they come with side effects. The recent announcement by Eli Lilly of their human trials for a new weight loss pill, orforglipron, shows promising results.
The trial found that participants lost an average of 12.4% of their body weight over 72 weeks, equivalent to about 27lbs. Although the company had initially hoped for 15% weight loss, this is still a significant achievement. Eli Lilly plans to submit orforglipron for regulatory review by year-end and aims for a global launch.
The new pill is expected to be cheaper to produce and easier to take than injections, which could make it more accessible to people seeking weight loss solutions. However, the results of the human trial were not as impressive as those of Mounjaro or Wegovy. Nevertheless, the pill form may offer reduced side effects compared to injections.
Dr. Simon Cork from Angela Ruskin University noted that the oral form of orforglipron would likely be more tolerable for patients and that manufacturing costs are expected to be lower than injectable drugs. If confirmed, this could make orforglipron a game-changer in the fight against obesity.
Source: https://www.ladbible.com/news/health/weight-loss-pill-human-nhs-trial-results-887748-20250808